00:03 , Dec 1, 2017 |  BC Week In Review  |  Company News

Shenogen, Lee's forge another cancer combo deal

Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) and Shenogen Pharma Group Ltd. (Beijing, China) partnered to jointly develop and commercialize a combination therapy in China to treat late-stage cancers. The therapy will comprise Lee's ZKAB001, which is...
22:01 , Nov 20, 2017 |  BC Extra  |  Company News

Shenogen, Lee's forge another cancer combo deal

Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) and Shenogen Pharma Group Ltd. (Beijing, China) partnered to jointly develop and commercialize a combination therapy in China to treat late-stage cancers. The therapy will comprise ZKAB001, which is a...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Lee’s Pharmaceutical Holdings Ltd., Shenogen Pharma deal

Lee’s Pharmaceutical and Shenogen partnered to develop and commercialize Lee’s Pharmaceutical’s Pexa-Vec in combination with Shenogen’s icaritin in China to treat late-stage cancers. The partners said a Phase II trial of icaritin to treat hepatocellular...
07:00 , Aug 24, 2016 |  BC Extra  |  Company News

Lee's, Shenogen to develop cancer combo therapy

Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) and Shenogen Pharma Group Ltd. (Beijing, China) plan to develop a combination therapy in China to treat late-stage cancers. The partners intend to investigate Pexa-Vec pexastimogene devacirepvec ( JX-594 ,...
07:00 , Aug 5, 2013 |  BioCentury  |  Finance

Runway in China

Runway in China With $20 million in hand from its recent series C round, Shenogen Pharma Group Ltd. hopes it can stretch the cash to both go public and get its lead program to market...
00:02 , Jul 11, 2013 |  BC Extra  |  Financial News

Shenogen raises $20 million in series C

Shenogen Pharma Group Ltd. (Beijing, China) raised $20 million in a series C round co-led by Legend Capital and Qiming Weichuang Venture Capital. Shenzhen Venture; China Investment Wealth Venture Fund; IDG Venture; and Lapam Venture...
08:00 , Feb 15, 2010 |  BC Week In Review  |  Company News

Optomagic, Shenogen Pharma deal

Optomagic's Chemizon Inc. drug discovery division and Shenogen will discover and develop small molecules targeting estrogen receptor alpha 36 to treat cancer and endocrine diseases. Chemizon will be responsible for lead optimization, assay development, ADME,...